

Mali has successfully stopped mass drug administration (MDA) for lymphatic filariasis in the country following interruption of transmission of the causative parasite in all districts. The last 15 remaining districts stopped MDA as of FY21 (October 2020 – September 2021).

Mali has successfully stopped MDA for onchocerciasis in two districts since 2016 where the national program is carrying out surveillance activities. The country has implemented in 2019-2020 serological assessments for onchocerciasis in border districts with Senegal, successfully demonstrating probable interruption of transmission in the Falemie river Basin.

Mali has one of the longest standing schistosomiasis/soil-transmitted helminthiasis (SCH/STH) control programs in West Africa, conducting SCH/STH MDA since 2004.
Mali was the first country to conduct community-based MDA SCH/STH at the sub-district level commencing in 2020.

Mali was selected by Task Force for Global Health to conduct a SCH oversampling survey in 2022, which will provide data for the country to re-assess treatment in 2022.
Standard Disease-Specific Indicators as of FY20
FY20 is October 2019 through September 2020

of ever-endemic districts have stopped MDA as of FY20
(i.e. have passed stop MDA survey, TAS1 (First Transmission Assessment Survey))*
*MDA has stopped in all districts
of ever-endemic districts in post-surveillance phase as of FY20
(i.e. have passed last surveillance survey, TAS3 (third Transmission Assessment Survey))
of persons no longer at risk as of FY20 among those who were ever at risk

of ever-endemic districts have stopped MDA as of FY20
(i.e. have passed stop MDA survey, TIS (Trachoma Impact Survey))*
* Trachoma not supported by USAID although endemic
No ever-endemic districts in post-surveillance phase as of FY20
(i.e. have passed surveillance survey, TSS (Trachoma Surveillance Survey))
of persons no longer at risk as of FY20 among those who were ever at risk

of ever endemic districts have been treated at least once as of FY20

of ever endemic districts have been treated at least once as of FY20
